These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25947396)

  • 1. Single-site Baseline and Short-term Outcomes of Clinical Characteristics and Life Quality Evaluation of Chinese Wet Age-related Macular Degeneration Patients in Routine Clinical Practice.
    Wang LL; Liu WJ; Liu HY; Xu X
    Chin Med J (Engl); 2015 May; 128(9):1154-9. PubMed ID: 25947396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study.
    Oshima Y; Ishibashi Y; Umeda N; Nagata T; Yoshida S; Uchio E; Kondo H; Sonoda KH; Ishibashi T
    BMC Ophthalmol; 2021 Jan; 21(1):58. PubMed ID: 33485320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting.
    Gomi F; Migita H; Sakaguchi T; Okada H; Sugawara T; Hikichi Y;
    Jpn J Ophthalmol; 2019 Nov; 63(6):437-447. PubMed ID: 31673841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
    Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
    Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.
    Bertelmann T; Feltgen N; Scheffler M; Hufenbach U; Wiedon A; Wilhelm H; Ziemssen F
    Health Qual Life Outcomes; 2016 Sep; 14(1):132. PubMed ID: 27644469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
    Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chinese Version of the Vision-Related Quality of Life (NEI-VFQ-25) among Patients with Various Ocular Disorders: A Pilot Study.
    Lee JS; Lin KK; Hou CH; Li PR; See LC
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice].
    Boulanger-Scemama E; Sayag D; Ha Chau Tran T; Quaranta-El Maftouhi M; Rumen F; Creuzot-Garcher C; Blanco Garavito R; Jung C; Souied E
    J Fr Ophtalmol; 2016 Oct; 39(8):668-674. PubMed ID: 27609025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration.
    Orr P; Rentz AM; Margolis MK; Revicki DA; Dolan CM; Colman S; Fine JT; Bressler NM
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3354-9. PubMed ID: 21282568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration.
    Revicki DA; Rentz AM; Harnam N; Thomas VS; Lanzetta P
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):712-7. PubMed ID: 19797233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration.
    van Asten F; Evers-Birkenkamp KU; van Lith-Verhoeven JJ; de Jong-Hesse Y; Hoppenreijs VP; Hommersom RF; Scholten AM; Hoyng CB; Klaver JH;
    Acta Ophthalmol; 2015 Mar; 93(2):126-33. PubMed ID: 25488348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
    Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
    Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study.
    Matamoros E; Maurel F; Léon N; Solomiac A; Bardoulat I; Joubert M; Hermans M; Moser E; Le Picard S; Souied EH; Leveziel N
    Ophthalmologica; 2015; 234(3):151-9. PubMed ID: 26337381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research.
    Wolf A; Kampik A
    Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):647-55. PubMed ID: 24424409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
    Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
    Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health- and vision-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at enrollment in a randomized trial of submacular surgery: Submacular Surgery Trials Report No. 5.
    Submacular Surgery Trials Research Group
    Arch Ophthalmol; 2005 Jan; 123(1):78-88. PubMed ID: 15642816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
    Feng L; Hu JH; Chen J; Xie X
    J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.